Human Activin Recombinant (CHO Cell)

//Human Activin Recombinant (CHO Cell)

Human Activin Recombinant (CHO Cell)

$380.00$3,700.00

SKU: RKP08476 Category: Tags: , , ,

accession P08476


Source Optimized DNA sequence encoding Human Inhibin Beta Alpha Chain was expressed in Chinese Hamster Ovary cell line.
Molecular weight Native humanActivin A is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 13 kDa. Recombinant Activin A is a glycosylated disulfide-linked homodimeric protein consisting of two alpha chain amino acid residue subunits, and migrates as an approximately 26 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity >97%, as determined by SDS-PAGE and HPLC
Biological Activity The ED(50) was determined by the dose-dependent proliferation ofmurine MCP11 cell line was found to be in the les than 1 ng/ml.

Protein Sequence MPLLWLRGFL LASCWIIVRS SPTPGSEGHS AAPDCPSCAL AALPKDVPNS 50 QPEMVEAVKK HILNMLHLKK RPDVTQPVPK AALLNAIRKL HVGKVGENGY 100 VEIEDDIGRR AEMNELMEQT SEIITFAESG TARKTLHFEI SKEGSDLSVV 150 ERAEVWLFLK VPKANRTRTK VTIRLFQQQK HPQGSLDTGE EAEEVGLKGE 200 RSELLLSEKV VDARKSTWHV FPVSSSIQRL LDQGKSSLDV RIACEQCQES 250 GASLVLLGKK KKKEEEGEGK KKGGGEGGAG ADEEKEQSHR PFLMLQARQS 300 EDHPHRRRRR GLECDGKVNI CCKKQFFVSF KDIGWNDWII APSGYHANYC 350 EGECPSHIAG TSGSSLSFHS TVINHYRMRG HSPFANLKSC CVPTKLRPMS 400 MLYYDDGQNI IKKDIQNMIV EECGCS 426
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation Human Activin A was lyophilized from a 0.2 μm filtered solution in 0.2M AcOH, pH 4.0.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers
Storage The lyophilized protein is stable for at least 2 years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.


Interactor P27037 AVR2A_HUMAN
Interactor P27038 AVR2A_MOUSE
Interactor P36896 ACV1B_HUMAN
Molecular function Growth-factor
Molecular function Hormone

Methods

Isolation, culture and 48 h induction of neural stem cells

  • For 48 h induction using serum-free conditions with growth factors, dissociated neurospheres were cultured with recombinant human (rh) BMP4 250 ng/mL , rh Activin A 100 ng/mL and rh bFGF 100 ng/mL individually as well as in combinations as indicated in Supporting Information Fig S1 and

Blimp1−/− EpiSC Derivation and Culture

  • EpiSCs were derived from E6.5 epiblasts by culturing on MEFs in medium'>N2B27 medium containing human activin A (20 ng/ml), bFGF (12 ng/ml), and KSR (20%) (

Directed differentiation of hESC-derived cysts to RPE using transwell filters.

100 ng/ml human Activin A
  • Ac+/Ac−: with or without Activin A.

Loss of REX1 within the pluripotent population primes cells for differentiation.

1 % FBS+100 ng/ml Activin A
  • n = 3 E) Fold enrichment of the percentage of GATA4 positive endoderm cells generated from TRA+VEN− cells relative to those from TRA+VEN+ population after 3 days of treatment with Activin A and BMP4 in low serum media, as observed by immunocytochemistry.

K02288 selectively inhibits BMP signaling.

100 ng/mL Activin A
  • Activin A-induced P-Smad2 in HEK293 cells was weakly inhibited by K02288 and LDN-193189.

Differentiation from human iPS cells toward hepatic lineage cells.

100 ng/ml recombinant human activin A
  • Human iPS cells were sequentially stimulated with various cytokines: (1) activin A, (2) basic FGF and BMP-4, and (3) HGF.

WNT3 Is a Functional Biomarker for Predicting the DE Differentiation Potential (A) WNT3 levels in control and various knockdown HUES8 sublines correlate with their DE differentiation efficiency.

100 ng/ml recombinant human activin A
  • The four protocols included the following treatments in a serum-free medium: (1) A - > A (Activin A only for 4 days); (2) AW - > A (Activin A and Wnt3a for 2 days followed by Activin A only for another 2 days); (3) A - > AX (Activin A only for 2 days followed by Activin A and XAV 939 for another 2 days); and (4) AW - > AX (Activin A and Wnt3a for 2 days followed by Activin A and XAV 939 for another 2 days).

Human ES cell culture and differentiation

  • Human H1, H9 and UCLA1-6 (UCLA stem cell core) [–1 bFGF .
  • EBs were differentiated according to previous reports with minor modification [μM Y27632 (Rho kinase inhibitor IV, EMD Chemicals), 3 ng ml−1 Activin A , 5 ng ml−1 bFGF, 10 ng ml−1 BMP4 and 5 μM IWR-1 (EMD Chemicals), for the first 4 days.
  • EBs were then cultured in StemPro 34 supplemented with 10 ng ml−1 bFGF, 5 ng ml–1 vascular endothelial growth factor (VEGF) and 5 μM IWR-1 for 5 additional days before plating onto elastic substrates.
  • Usage of all human ES cell lines is approved by the UCLA Embryonic Stem Cell Research Oversight (ESCRO) Committee and the Institutional Review Boards (IRB, approval #2009-006-04).

Induction of hESCs into primitive streak (PS) cells.

both 100 ng/ml Activin A
  • (b) Comparison of expression levels of PS specific genes by combinatorial treatments with exogenous factors of Activin A, Wnt3a and BMP4, FGF2 , in hESC-derived PS cells.

Differentiation of human ESC and iPSC into definitive endoderm

  • Differentiation into definitive endoderm was performed as previously described.
  • Briefly, pluripotent stem cells were harvested, gently triturated into single cell suspensions and seeded onto transwells (0.4μm pore size, Corning) pre-coated with human placental collagen Type IV, which has previously been shown to support airway epithelial cell growth.
  • The cells were immediately treated with 100ng/ml Activin-A and 25ng/ml WNT3A for 4 consecutive days in Endoderm ifferentiation Media consisting of serum-free Knockout MEM with Glutamax , penicillin/streptomycin (GIBCO), 1 mM nonessential amino acids (GIBCO) and 0.5 mM mercaptoethanol.
  • Subsequent differentiation steps were performed on the transwells.